Characteristics of older and younger adults with acute myeloid leukemia (AML).
| Characteristic . | Older AML PatientsA . | Younger AML PatientsA . |
|---|---|---|
| A In general, Older AML Patients are defined as ≥ 60 years of age; Younger AML Patients as < 60 years of age. | ||
| B New diagnoses, per 100,000 US citizens per year. Older/younger division occurs at 65 years. | ||
| C Percentages rounded to nearest whole number | ||
| D Rates following remission-induction therapy with an anthracycline- or anthracenedione-based regimen. | ||
| Population incidenceB | 17.6 | 1.8 |
| Favorable cytogeneticsC | ||
| t(8;21) | 2% | 9% |
| inv 16 or t(16;16) | 1–3% | 10% |
| t(15;17) | 4% | 6–12% |
| Unfavorable cytogeneticsC | ||
| −7 | 8–9% | 3% |
| +8 | 6–10% | 4% |
| Complex | 18% | 7% |
| MDR1 expression | 71% | 35% |
| Secondary AML | 24–56% | 8% |
| Treatment-related mortalityD | 25–30% | 5–10% |
| Complete remissionD | 38–62% | 65–73% |
| Long-term survivalC | 5–15% | 30% |
| Characteristic . | Older AML PatientsA . | Younger AML PatientsA . |
|---|---|---|
| A In general, Older AML Patients are defined as ≥ 60 years of age; Younger AML Patients as < 60 years of age. | ||
| B New diagnoses, per 100,000 US citizens per year. Older/younger division occurs at 65 years. | ||
| C Percentages rounded to nearest whole number | ||
| D Rates following remission-induction therapy with an anthracycline- or anthracenedione-based regimen. | ||
| Population incidenceB | 17.6 | 1.8 |
| Favorable cytogeneticsC | ||
| t(8;21) | 2% | 9% |
| inv 16 or t(16;16) | 1–3% | 10% |
| t(15;17) | 4% | 6–12% |
| Unfavorable cytogeneticsC | ||
| −7 | 8–9% | 3% |
| +8 | 6–10% | 4% |
| Complex | 18% | 7% |
| MDR1 expression | 71% | 35% |
| Secondary AML | 24–56% | 8% |
| Treatment-related mortalityD | 25–30% | 5–10% |
| Complete remissionD | 38–62% | 65–73% |
| Long-term survivalC | 5–15% | 30% |